Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Trading Floor Community IconFrom the Trading Floor:
Intellia Therapeutics Inc Logo

Combined Holdings of Intellia Therapeutics (NTLA) - Updated Daily

Lock IconJoin Premium Plan
The Bucket Report Icon
Download ARK WatchlistsDownload ARK holdings as watchlists that can be imported into TradingView and Interactive Brokers
Date
Direction
Shares
Fund Weight
Fund
April 14, 2022BUY43.968k0.0243%ARKK
April 14, 2022BUY13.763k0.0248%ARKG
April 13, 2022BUY1.109k0.002%ARKG
April 13, 2022BUY3.543k0.002%ARKK
April 12, 2022BUY5.691k0.0104%ARKG

Key Statistics

Upcoming EarningsSee Full Calendar
DateAugust 03, 2022(Est)Revenue
Expected$9.42m
Actual▫️
EPS
Expected-$1.31
Actual▫️
🕵🏼Found In🏷Last Price
ARKKARKG$54.01
⚖️Weighting🧢Market Cap
2.78%$4.10b
🏋️‍♀️Weight Rank Across All Funds🧮Price to Sales
11108.21
💳ARK Estimated Cost Average🌏Country
$54.51 - ARKG$62.04 - ARKK
🇺🇸United States
🎫ARK Ownership Percent
10.74%
Description
Intellia Therapeutics is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products.
Website
www.intelliatx.com